Rossing P, Caramori ML, Chan JCH et al (2022) KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 102:S1–S127. https://doi.org/10.1016/j.kint.2022.06.008

Article  Google Scholar 

Bakris GL, Molitch M (2018) Are all patients with type 1 diabetes destined for dialysis if they live long enough? Probably not. Diabetes Care 41:389–390. https://doi.org/10.2337/dci17-0047

Article  PubMed  Google Scholar 

Dena M, Svensson AM, Olofsson KE et al (2021) Renal complications and duration of diabetes: an international comparison in persons with type 1 diabetes. Diabetes Ther 12(12):3093–3105. https://doi.org/10.1007/s13300-021-01169-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jansson Sigfrids F, Groop PH, Harjutsalo V (2022) Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0–14 years: a population-based retrospective cohort study. Lancet Diabetes Endocrinol 10:489–498. https://doi.org/10.1016/S2213-8587(22)00099-7

Article  CAS  PubMed  Google Scholar 

Halminen J, Sattaer N, Rawshani A et al (2022) Range of risk factor levels, risk control, and temporal trends for nephropathy and end-stage kidney disease in patients with type 1 and type 2 diabetes. Diabetes Care 45:2326–2335. https://doi.org/10.2337/dc22-0926

Article  PubMed  Google Scholar 

Graves L, Donaghue K (2019) Management of diabetes complications in youth. Ther Adv Endocrinol Metab 10:2042018819863226. https://doi.org/10.1177/2042018819863226

Article  PubMed  PubMed Central  Google Scholar 

Kristofi R, Bodegard J, Norhammar A et al (2021) Cardiovascular and renal disease burden in type 1 compared with type 2 diabetes: a two-country nationwide observational study. Diabetes Care 44:1211–1218. https://doi.org/10.2337/dc20-2839

Article  CAS  PubMed  PubMed Central  Google Scholar 

McAllister DA, Read SH, Kerssens J et al (2018) Incidence of hospitalization for heart failure and case-fatality among 3.25 million people with and without diabetes mellitus. Circulation 138:2774–2786. https://doi.org/10.1161/CIRCULATIONAHA.118.034986

Article  PubMed  PubMed Central  Google Scholar 

Mohandes S, Doke T, Hu H, Mukhi D, Dhillon P, Susztak K (2023) Molecular pathways that drive diabetic kidney disease. J Clin Invest 133:e165654. https://doi.org/10.1172/JCI165654

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mora-Fernández C, Dominguez-Pimentel V, Muros de Fuentes M, Gorriz JL, Martinez-Castelao A, Navarro-Gonzalez JF (2014) Diabetic kidney disease: from physiology to therapeutics. J Physiol 592:3997–4009. https://doi.org/10.1113/jphysiol.2014.272328

Article  CAS  PubMed  PubMed Central  Google Scholar 

Forbes JM, Thorburn DR (2018) Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol 14:291–312. https://doi.org/10.1038/nrneph.2018.9

Article  CAS  PubMed  Google Scholar 

Tan ALY, Forbes JM, Cooper ME (2007) AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27:130–143. https://doi.org/10.1016/j.semnephrol.2007.01.006

Article  CAS  PubMed  Google Scholar 

Giacchetti G, Sechi LA, Rilli S, Carey RM (2005) The renin-angiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 16:120–126. https://doi.org/10.1016/j.tem.2005.02.003

Article  CAS  PubMed  Google Scholar 

Leehey DJ, Singh AK, Alavi N, Singh R (2000) Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 58(Suppl 77):S93-98. https://doi.org/10.1046/j.1523-1755.2000.07715.x

Article  Google Scholar 

Lytvyn Y, Godoy LC, Scholtes RA, van Raalte DH, Cherney DZ (2019) Mineralocorticoid antagonism and diabetic kidney disease. Curr Diab Rep 19:4. https://doi.org/10.1007/s11892-019-1123-8

Article  CAS  PubMed  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR et al (2023) 10. Cardiovascular disease and risk management: standards of care in diabetes-2023. Diabetes Care 46:S158–S190. https://doi.org/10.2337/dc23-S010

Article  CAS  PubMed  Google Scholar 

Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:99–111. https://doi.org/10.1001/jama.287.19.2563

Article  Google Scholar 

de Boer IH, DCCT/EDIC Research Group (2014) Kidney disease and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Care 37:24–30. https://doi.org/10.2337/dc13-2113

Article  CAS  PubMed  Google Scholar 

Lewis E, Hunsicker L, Bain R, Rohde R (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Eng J Med 329(20):1456–1462. https://doi.org/10.1056/NEJM199311113292004

Article  CAS  Google Scholar 

EUCLID Study Group (1997) Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349:1787–1792. https://doi.org/10.1016/S0140-6736(96)10244-0

Article  Google Scholar 

Strippoli GFM, Bonifati C, Craig M, Navaneethan SD, Craig JC (2006) Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 4:CD006257. https://doi.org/10.1002/14651858.CD006257

Article  Google Scholar 

Mauer M, Zinman B, Gardiner R et al (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes (RASS). N Engl J Med 361:40–51. https://doi.org/10.1056/NEJMoa0808400

Article  CAS  PubMed  PubMed Central  Google Scholar 

Doria A, Galecki AT, Spino C et al (2020) Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med 382:2493–2503. https://doi.org/10.1056/NEJMoa1916624

Article  CAS  PubMed  PubMed Central  Google Scholar 

ElSayed NA, Aleppo G, Aroda VR et al (2023) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023. Diabetes Care 46:S140–S157. https://doi.org/10.2337/dc23-S009

Article  CAS  PubMed  Google Scholar 

Botana M, Escalada J, Merchante Á, Reyes R, Rozas P (2022) Prevention of cardiorenal complications with sodium–glucose cotransporter type 2 inhibitors: a narrative review. Diabetes Ther 13:5–17. https://doi.org/10.1007/s13300-022-01277-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306. https://doi.org/10.1056/NEJMoa1811744

Article  CAS  PubMed  Google Scholar 

Heerspink HJL, Stefansson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436–1446. https://doi.org/10.1056/NEJMoa2024816

Article  CAS  PubMed  Google Scholar 

EMPA-KIDNEY Collaborative Group (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117–127. https://doi.org/10.1056/NEJMoa2204233

Article  Google Scholar 

Liu H, Sridhar VS, Boulet J et al (2022) Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism 126:154918. https://doi.org/10.1016/j.metabol.2021.154918

Article  CAS  PubMed  Google Scholar 

Laursen JC, Sondergaard-Heinrich N, Lopes de Melo JM et al (2021) Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: a randomised, double-blind, placebo-controlled crossover trial. eClinicalMedicine 37:100895. https://doi.org/10.1016/j.eclinm.2021.100895

Article  PubMed  PubMed Central  Google Scholar 

Schaub JA, AlAkwaa FM, McCown PJ et al (2023) SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth onset type 2 diabetes. J Clin Invest 133(5):e164486. https://doi.org/10.1172/JCI164486

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baigent C, Emberson JR, Haynes R et al (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400:1788–1801. https://doi.org/10.1016/S0140-6736(22)02074-8

Article  Google Scholar 

Rodbard HW, Giaccari A, Lajara R et al (2020) Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2. Diabetes Obes Metab 22:2089–2096. https://doi.org/10.1111/dom.14127

Article  CAS  PubMed  Google Scholar 

Garg SK, Henry RR, Banks P et al (2017) Effects of Sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 377:2337–2348. https://doi.org/10.1056/NEJMoa1708337

Article  CAS  PubMed  Google Scholar 

Rosenstock J, Marquard J, Laffel LM et al (2018) Empagliflozin as adjunctive to insulin therapy